STOCK TITAN

Castle Biosciences Inc - CSTL STOCK NEWS

Welcome to our dedicated news page for Castle Biosciences (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Castle Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Castle Biosciences's position in the market.

Rhea-AI Summary
Study shows DecisionDx-Melanoma test outperforms MSKCC nomogram in predicting risk of SLN positivity in patients with melanoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
none
-
Rhea-AI Summary
Castle Biosciences, Inc. will present new data at the ASTRO 2023 Annual Meeting demonstrating the ability of its DecisionDx®-SCC test to identify node-negative cutaneous squamous cell carcinoma (SCC) patients at a higher risk of metastasis who may benefit from adjuvant radiation therapy (ART). The test significantly stratified the cohort according to risk of metastasis, with metastasis-free survival rates of 92.4%, 76.1%, and 59.4% for patients with Class 1, Class 2A, and Class 2B test results, respectively. This could guide risk-aligned treatment decisions and potentially de-intensify treatment for some patients. Abstracts will be published in the International Journal of Radiation Oncology • Biology • Physics (Red Journal).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.75%
Tags
none
-
Rhea-AI Summary
Castle Biosciences, Inc. presents data showing clinical utility of its TissueCypher® Barrett’s Esophagus test in guiding risk-aligned upstaging of care for patients with non-dysplastic Barrett’s esophagus (NDBE) at a higher risk of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
none
Rhea-AI Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) will ring the Nasdaq closing bell on Sept. 27 to raise awareness of melanoma. Their DecisionDx-Melanoma test improves health outcomes for patients with melanoma. Melanoma claims nearly 20 American lives each day. Castle's test provides personalized information about a patient's risk of recurrence, metastasis, and lymph node positivity. The company will also ring the NYSE closing bell on Sept. 28 to celebrate the launch of the Texas Capital Texas Equity Index ETF.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Castle Biosciences' TissueCypher test outperforms standard pathology review in predicting progression to esophageal cancer in Barrett's esophagus patients with initial low-grade dysplasia diagnosis, according to a study published in Gastroenterology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
none
-
Rhea-AI Summary
Castle Biosciences, Inc. receives Clinical Laboratory Permit for its Pittsburgh laboratory from the New York State Department of Health, expanding its ability to impact patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
none
Rhea-AI Summary
Castle Biosciences, Inc. announces data showing IDgenetix test significantly improves remission rates for patients with depression
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Castle Biosciences to present data on the risk stratification performance of its TissueCypher test for Barrett's Esophagus at the 19th ISDE World Congress for Esophageal Diseases. The test identified a subset of patients with non-dysplastic Barrett's esophagus (NDBE) who had a similar risk of progression to high-grade dysplasia/esophageal adenocarcinoma as patients with low-grade dysplasia. TissueCypher also identified low-risk subsets of patients whose care could be de-escalated and managed with surveillance only. The data suggest that the use of TissueCypher could increase early detection and benefit patients at higher risk of progression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Castle Biosciences to present new data on IDgenetix test at Psych Congress 2023 conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
Rhea-AI Summary
Castle Biosciences to present at Baird’s Global Healthcare Conference and Lake Street Best Ideas Growth Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
conferences
Castle Biosciences Inc

Nasdaq:CSTL

CSTL Rankings

CSTL Stock Data

608.02M
26.61M
4.31%
89.98%
5.17%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Friendswood

About CSTL

castle biosciences, inc. specializes in diagnostic tests for cancers. founded in 2008, the company goal has been to help advance the care for cancers through objective testing. our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. currently, castle biosciences has tests to help doctors treat cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma and glioma. we have active research programs in rectal cancer and soft tissue sarcoma, and anticipate tests for these and other under-served cancers to be available in the near future please visit us at www.castlebiosciences.com for more information on our company and products.